TENX
TENAX THERAPEUTICS, INC.
Key Financials
Gross Profit
$0
NaN%
Revenue
$0
NaN%
Net Income
$-52599000
↓ 198.8%
EPS (Diluted)
$-1.34
↓ 16.5%
Shareholders' Equity
$97.1M
↑ 5.5%
Total Assets
$104.2M
↑ 7.8%
Cash & Equivalents
$97.6M
↑ 2.8%
Total Liabilities
$7.2M
↑ 52.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 9/17/2026 | View on SEC |
| 4 | 9/15/2026 | View on SEC |
| 4 | 9/15/2026 | View on SEC |
| SCHEDULE 13G/A | 9/11/2026 | View on SEC |
| 8-K | 9/9/2026 | View on SEC |
| 4 | 9/8/2026 | View on SEC |
| SCHEDULE 13G | 9/8/2026 | View on SEC |
| SCHEDULE 13G/A | 9/8/2026 | View on SEC |
| 4 | 9/2/2026 | View on SEC |
| SCHEDULE 13G | 8/27/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TENX |
| Company Name | TENAX THERAPEUTICS, INC. |
| CIK | 34956 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 919-855-2100 |